Abstract
Several reports have defined nonfamilial thrombotic thrombocytopenic purpura (TTP) as an autoimmune disorder caused by antibodies to von Willebrand’s factor-cleaving protease (vWF-CP). This raises the possibility that rituximab, a monoclonal antibody against CD20 present in B-lymphoid cells, may have utility in the treatment of TTP. We report five consecutively treated patients with relapsed TTP who responded rapidly to immune suppression by rituximab at our institution. These two male and three female patients had a median age of 37 years (27–70). The median time from diagnosis to therapy was 24 months (8–60). Prior therapies included plasma exchange and corticosteroids in all cases, splenectomy (4), vincristine and aspirin (3), and azathioprine (2). The median number of plasma exchanges received prior to therapy was 59 (21–158). The cohort had a median platelet count of 48×109/l (23–110), median hemoglobin of 9 g/dl (8–11), and median lactate dehydrogenase of 632 IU/l (311–945) prior to administration of rituximab. Analysis of vWF-CP activity demonstrated absent or decreased activity with detectable inhibitors in four patients. All patients attained a complete response. The median time to response after the first dose of rituximab was 5 weeks. Responses are maintained in all patients from 10 to 21 months after treatment. This report adds to the evidence that rituximab has efficacy in nonfamilial TTP and warrants further study.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bell WR, Braine HG, Ness PM, Kickler TS (1991) Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: clinical experience in 108 patients. N Engl J Med 325:398–403
Chemnitz J, Draube A, Scheid C, Staib P, Schulz A, Diehl V, Sohngen D (2002) Successful treatment of severe thrombotic thrombocytopenic purpura with monoclonal antibody rituximab. Am J Hematol 71:105–108
Ferrara F, Copia C, Annunziata M, Spasiano A, DiGrazia C, Palmieri S, Prossomariti L, Mele G (1999) Vincristine as salvage treatment for refractory thrombotic thrombocytopenic purpura. Ann Hematol 78:521–523
Furlan M, Robles R, Lammle B (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87:4223–4234
Gutterman L, Kloster B, Tsai H (2002) Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 28:385–391
Hayward CP, Sutton DM, Carter WH Jr, Campbell ED, Scott JG, Francombe WH, Shumak KH, Baker MA (1994) Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Arch Intern Med 154:982–987
Mangel J, Buckstein R, Imrie K, Spaner D, Franssen E, Pavlin P, Boudreau A, Pennell N, Combs D, Berinstein NL (2003) Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as ‘in vivo purge’ and consolidative immunotherapy following autologous stem cell transplantation. Ann Oncol 14:758–765
Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A (2001) Treatment of childhood autoimmune hemolytic anemia with rituximab. Lancet 358:1511–1513
Rizvi MA, Vesely SK, George JN, Schandler L, Duvall D, Smith JW, Gilcher RO (2000) Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremia syndrome. Transfusion 40:896–901
Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA (1991) Canadian Apheresis Study Group. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 325:393–397
Rosove MH, Ho WG, Goldfinger D (1982) Ineffectiveness of aspirin and dipyridamole in the treatment of thrombotic thrombocytopenic purpura. Ann Intern Med 96:27–33
Sahud MA, Clastter S, Liu L, Ero M, Harris K, Furlan M (2002) von Willebrand factor-cleaving protease inhibitor in a patient with human immunodeficiency syndrome-associated thrombotic thrombocytopenic purpura. Br J Haematol 116:909–911
Scheiflinger F, Knobl P, Trattner B, Plaimauer B, Mohr G, Dockal M, Dorner F, Rieger M (2003) Non neutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 102:3241–3243
Shanafelt TD, Madueme HL, Wolf RC, Tefferi A (2003) Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 78:1340–1346
Shumak KH, Rock GA, Nair RC (1995) Canadian Apheresis Group. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Ann Intern Med 122:569–572
Stasi R, Pagano A, Stipa E, Amadori S (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98:952–957
Stewart M, Malkovska V, Krishnan J, Lessin L, Barth W (2001) Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab. Ann Rheum Dis 60:892–893
Tsai HM (1996) Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 8:4235–4244
Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585–1594
Tsai HM, Shulman K (2003) Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol 70:183–185
Veltman GA, Brand A, Leeksma OC, ten Bosch GJ, van Krieken JH, Briet E (1995) The role of splenectomy in the treatment of relapsing thrombotic thrombocytopenic purpura. Ann Hematol 70:231–236
Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peeschke EI, Weksler BB, Schechter GP (2002) Rituximab in the treatment of acquired factor VIII inhibitors. Blood 100:3426–3428
Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai HM (2004) Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of literature. Br J Haematol 124:787–795
Zheng X, Chug D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K (2001) Structure of von Willebrand factor-cleaving protease (ADAMTS 13): a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276:41059–41063
Zheng X, Pellera AM, Goodnough LT, Sadler JE, Blinder MA (2003) Remission of chronic thrombotic thrombocytopenia purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 138:105–108
Acknowledgments
Authors would like to thank Michael S. Welch for his assistance with illustrations. Declaration Authors declare that this report complies with the current laws of the United States of America.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Reddy, P.S., Deauna-Limayo, D., Cook, J.D. et al. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol 84, 232–235 (2005). https://doi.org/10.1007/s00277-004-0964-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-004-0964-6